../ IS  
Útgefið gæðaskjal: Leiðbeiningar
Skjalnúmer: Rklín-489
Útg.dags.: 01/08/2019
Útgáfa: 3.0
2.02.03.02.01 Amfetamín

Samheiti: Metamphetamín (MET), Amphetamin (AMP)


Hide details for Sýnataka, geymsla og sýnasending Sýnataka, geymsla og sýnasending
Gerð sýnis : Þvag, sermi (má líka vera EDTA-,heparín- cítrat-plasma eða serum)

Magn: Min 10 mL þvag eða 2 mL sermis eða plasma.
Geymsla sýnis: Kælir.
Sýnasending: Hraðsending í umhverfishita.
Hide details for Heiti tilvísunarannsóknastofu og heimilisfangHeiti tilvísunarannsóknastofu og heimilisfang
MVZ Labor PD Dr. Volkmann und Kollegen GbR
Kriegsstrasse 99
76133 Karlsruhe

Tel:  0721 85000-0
Fax: 0721 85000-199

www.laborvolkmann.de
E-Mail:
 labor@laborvolkmann.de
Hide details for HeimildirHeimildir
Amphetamine

MVZ Labor PD Dr. Volkmann und Kollegen GbR 1 10.09.2013

Screening Semiquantitative Bestimmung im Urin (CEDIA) von:
Amphetamine
Methamphetamine
MDA (Methylendioxyamphetamin, Ecstasy-Begleitstoff und -Metabolit)
MDMA (Methylendioxymetamphetamin, Ecstasy)
MDEA (3,4-Methylendioxy-N-ethylamphetamin)
MBDB (N-Methyl-1-(1,3-Benzodioxol-5-yl)-2-butanamin)
BDB (1-(1,3-Benzodioxol-5-yl)-2-butanamin)
Bestätigungstest Quantitative Bestimmung im Urin oder Serum / Plasma (LC-MS/MS) von:
Amphetaminen
Methamphetaminen
MDMA
Material Screening Urin, 10 mL
Bestätigung Urin, 10 mL und
Serum, Heparin-Plasma, EDTA-Plasma oder Citrat-Plasma, 2 mL
Cut off Screening [ng/mL]
Urin 500
Bestätigung
Urin 25 Bestimmungsgrenze
Serum / Plasma 20


amphetamine.pdfamphetamine.pdf

Semiquantitative Bestimmung im Urin (CEDIA) von:
Amphetamine
Methamphetamine
MDA (Methylendioxyamphetamin, Ecstasy-Begleitstoff und -Metabolit)
MDMA (Methylendioxymetamphetamin, Ecstasy)
MDEA (3,4-Methylendioxy-N-ethylamphetamin)
MBDB (N-Methyl-1-(1,3-Benzodioxol-5-yl)-2-butanamin)
BDB (1-(1,3-Benzodioxol-5-yl)-2-butanamin)

Skimun (screening) í þvagi næmni (cut off) 500 ng/ml eða staðfesting næmni 25ng/ml í þvagi og 20 ng/ml í sermi (plasma).

Fróðleikur:
Amphetamine activates receptors in the brain and increases the activity of a number of neurotransmitters, especially norepinephrine and dopamine. Dopamine is associated with pleasure, movement, and attention. Amphetamine has been trialed for a wide variety of conditions. Now, it is mainly used to treat ADHD, and, rarely, depression. In the past, it has been used to treat narcolepsy and to help with weight loss, but this is less common now.
Side Effects
Amphetamines can produce severe systemic effects, including cardiac irregularities and gastric disturbances. Chronic use often results in insomnia, hyperactivity, irritability, and aggressive behavior. Addiction can result in psychosis or death from overexhaustion or cardiac arrest. Amphetamine-induced psychosis often mimics schizophrenia, with paranoia and hallucinations.

Ritstjórn

Ingibjörg Loftsdóttir
Sigrún H Pétursdóttir
Guðmundur Sigþórsson
Kristín Sigurgeirsdóttir

Samþykkjendur

Ábyrgðarmaður

Ísleifur Ólafsson

Útgefandi

Sigrún H Pétursdóttir

Upp »


Skjal fyrst lesið þann 06/09/2016 hefur verið lesið 407 sinnum